X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to advance the commercialization of APHEXDA (motixafortide) approved with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.
Lead Product(s): Motixafortide,Filgrastim
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: BlackRock
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 10, 2024
Details:
BioLineRx intends to use the proceeds to support the commercialization of APHEXDA (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in patients with multiple myeloma.
Lead Product(s): Motixafortide,Filgrastim
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: JonesTrading Institutional Services
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 01, 2024
Details:
BL-8040 (motixafortide) is a CXCR4 inhibitor, which is being evaluated in combination with cemiplimab, and standard of care chemotherapies for the treatment of Pancreatic ductal adenocarcinoma.
Lead Product(s): Motixafortide,Cemiplimab,Gemcitabine
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
BioLineRx initiated Phase I clinical trial studies evaluating BL-8040 (motixafortide), CXCR4/SDF-1 inhibitor, as monotherapy and in combination with natalizumab for the treatment of sickle cell disease.
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Hematology Product Name: BL-8040
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Gloria Biosciences
Deal Size: $279.6 million Upfront Cash: $29.6 million
Deal Type: Licensing Agreement October 31, 2023
Details:
Aphexda (motixafortide) is a CXCR4 antagonist , which is investigated in combination with gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancers.
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
APHEXDA (motixafortide) is a CXCR4 antagonist , which is investigated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
Lead Product(s): Motixafortide,G-CSF
Therapeutic Area: Oncology Product Name: Aphexda
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
BL-8040 (motixafortide) inhibits CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers including pancreatic ductal adenocarcinoma (PDAC).
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Oncology Product Name: BL-8040
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
The aim of the collaboration is to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of BL-8040 (motixafortide) to mobilize CD34+ hematopoietic stem cells (HSCs) for gene therapies in sickle cell disease (SCD).
Lead Product(s): Motixafortide,Natalizumab
Therapeutic Area: Genetic Disease Product Name: BL-8040
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Washington University School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 06, 2023
Details:
AGI-134 is a synthetic alpha-Gal glycolipid in development for solid tumors that is highly differentiated from other cancer immunotherapies. AGI-134 is designed to label cancer cells with alpha-Gal via intra-tumoral administration.
Lead Product(s): AGI-134
Therapeutic Area: Oncology Product Name: AGI-134
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
